XXXX -positive @entity775 .

@entity2835 @entity1 @entity2383 @entity21640 @entity15706 @entity2388 @entity775
UNASSIGNED: @entity2383 ( @entity2383 ) is specific to @entity2835 ( @entity2835 ), but can also be found in certain @entity1 with @entity775 ( @entity775 ). Effective methods of differentiating between @entity2835 and @entity775 are required, as their clinical course and management are different. Titers of @entity2383 were analyzed before and after follow-up in @entity1 with @entity2835 or @entity775 . @entity1 who underwent liver biopsy and were diagnosed with either @entity775 (10 @entity1 ) or @entity2835 (3 @entity1 ) were enrolled in the study. The @entity2383 antibody titers of these @entity1 were analyzed upon hospital admission. @entity2383 reacted with the @entity2388 dehydrogenase complex-E2, branched-chain @entity21640 dehydrogenase complex and @entity15706 dehydrogenase complex in the assay utilized for this study. The cut-off value for @entity2383 was 5. Six @entity775 @entity1 were @entity2383 (-) and 4 were @entity2383 (+). The titer for the @entity775 @entity1 who were @entity2383 (+) was 24.8  14.8, compared with 324  174 in the @entity1 with @entity2835 (P=0.0138). Three @entity2383 (+) @entity775 @entity1 were followed-up after liver biopsy. The @entity2383 levels had decreased in all 3 @entity1 , becoming undetectable in 2 of them. In conclusion, certain @entity1 with @entity775 in this study were found to be @entity2383 (+), but the titers were significantly lower than those in the @entity1 with @entity2835 . At follow-up, the @entity775 @entity1 exhibited @entity2383 .
